DE69735274T2 - Verfahren zur herstellung von rekombinanten viren - Google Patents

Verfahren zur herstellung von rekombinanten viren Download PDF

Info

Publication number
DE69735274T2
DE69735274T2 DE69735274T DE69735274T DE69735274T2 DE 69735274 T2 DE69735274 T2 DE 69735274T2 DE 69735274 T DE69735274 T DE 69735274T DE 69735274 T DE69735274 T DE 69735274T DE 69735274 T2 DE69735274 T2 DE 69735274T2
Authority
DE
Germany
Prior art keywords
baculovirus
genome
recombinant
adenovirus
defective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735274T
Other languages
German (de)
English (en)
Other versions
DE69735274D1 (de
Inventor
Helène LEBLOIS-PREHAUD
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centelion SAS
Original Assignee
Centelion SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9497899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69735274(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centelion SAS filed Critical Centelion SAS
Application granted granted Critical
Publication of DE69735274D1 publication Critical patent/DE69735274D1/de
Publication of DE69735274T2 publication Critical patent/DE69735274T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pens And Brushes (AREA)
  • Materials For Medical Uses (AREA)
DE69735274T 1996-11-22 1997-11-18 Verfahren zur herstellung von rekombinanten viren Expired - Lifetime DE69735274T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9614278 1996-11-22
FR9614278A FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants
PCT/FR1997/002073 WO1998022607A1 (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants

Publications (2)

Publication Number Publication Date
DE69735274D1 DE69735274D1 (de) 2006-04-20
DE69735274T2 true DE69735274T2 (de) 2006-10-12

Family

ID=9497899

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735274T Expired - Lifetime DE69735274T2 (de) 1996-11-22 1997-11-18 Verfahren zur herstellung von rekombinanten viren

Country Status (18)

Country Link
US (2) US6387670B1 (https=)
EP (1) EP0946741B1 (https=)
JP (1) JP4686670B2 (https=)
KR (1) KR100719645B1 (https=)
AT (1) ATE317908T1 (https=)
AU (1) AU731106B2 (https=)
BR (1) BR9713388B1 (https=)
CA (1) CA2271438C (https=)
CZ (1) CZ293947B6 (https=)
DE (1) DE69735274T2 (https=)
ES (1) ES2260803T3 (https=)
FR (1) FR2756297B1 (https=)
HU (1) HU224713B1 (https=)
IL (1) IL129686A (https=)
NO (2) NO323937B1 (https=)
SK (1) SK286900B6 (https=)
WO (1) WO1998022607A1 (https=)
ZA (1) ZA9710516B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501042A (ja) * 1999-05-27 2003-01-14 ジェノボ， インコーポレイテッド 非哺乳動物ウイルス由来のキャリアベクターを使用する、組換えウイルスの産生のための組成物および方法
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
GB9919409D0 (en) 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
WO2004020605A2 (en) * 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2249950B1 (en) * 2008-03-05 2014-10-15 Council of Scientific & Industrial Research A polymeric hybrid membrane
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
CN102884196B (zh) * 2010-04-01 2015-05-06 肖卫东 重组病毒载体的结构及其制备
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2013190059A1 (en) 2012-06-21 2013-12-27 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
EP3039129B1 (en) * 2013-08-30 2018-06-27 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
MX2020005470A (es) 2017-11-27 2020-11-09 Coda Biotherapeutics Inc Composiciones y metodos para enfermedades neurologicas.
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
CN111902164A (zh) 2018-02-01 2020-11-06 同源药物公司 用于恢复pah基因功能的腺相关病毒组合物及其使用方法
CN112041437A (zh) 2018-02-19 2020-12-04 同源药物公司 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
WO2019215644A1 (en) 2018-05-08 2019-11-14 Neuracle Science Co., Ltd. Adeno-associated virus (aav) delivery of anti-fam19a5 antibodies
KR20210130158A (ko) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
JP7781052B2 (ja) 2019-08-21 2025-12-05 トレイムス バイオ， インコーポレイテッド 神経学的疾患のための組成物および方法
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
AU2021358957A1 (en) 2020-10-07 2023-06-08 AskBio Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
US20250296996A1 (en) 2022-04-29 2025-09-25 Broadwing Bio, Inc. Angiopoietin-related protein 7-specific antibodies and uses thereof
US20250346653A1 (en) 2022-04-29 2025-11-13 Broadwing Bio Inc. Bispecific antibodies and method of treating ocular disease
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
WO2025040613A1 (en) * 2023-08-21 2025-02-27 Vector Biopharma Ag Cell line for production of helper-dependent adenoviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92298A (en) * 1988-11-14 2001-04-30 Us Secretary U S Dept Of Comme Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
CA2200835A1 (en) * 1994-09-23 1996-03-28 Frederick M. Boyce Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell

Also Published As

Publication number Publication date
NO992464L (no) 1999-06-23
US20030022356A1 (en) 2003-01-30
IL129686A (en) 2005-12-18
KR20000057202A (ko) 2000-09-15
ZA9710516B (en) 1998-06-10
EP0946741A1 (fr) 1999-10-06
HUP0001762A2 (hu) 2000-09-28
KR100719645B1 (ko) 2007-05-17
CZ293947B6 (cs) 2004-08-18
WO1998022607A1 (fr) 1998-05-28
NO992464D0 (no) 1999-05-21
SK66699A3 (en) 2000-02-14
NO2013009I1 (no) 2013-04-29
ATE317908T1 (de) 2006-03-15
BR9713388B1 (pt) 2009-01-13
AU5226198A (en) 1998-06-10
AU731106B2 (en) 2001-03-22
BR9713388A (pt) 2000-03-21
HU224713B1 (en) 2006-01-30
JP2001503993A (ja) 2001-03-27
IL129686A0 (en) 2000-02-29
CA2271438A1 (fr) 1998-05-28
EP0946741B1 (fr) 2006-02-15
FR2756297B1 (fr) 1999-01-08
HUP0001762A3 (en) 2002-01-28
FR2756297A1 (fr) 1998-05-29
NO323937B1 (no) 2007-07-23
CA2271438C (fr) 2010-10-26
DE69735274D1 (de) 2006-04-20
US6387670B1 (en) 2002-05-14
ES2260803T3 (es) 2006-11-01
CZ182299A3 (cs) 1999-08-11
JP4686670B2 (ja) 2011-05-25
SK286900B6 (sk) 2009-07-06

Similar Documents

Publication Publication Date Title
DE69735274T2 (de) Verfahren zur herstellung von rekombinanten viren
DE60121471T2 (de) Komplementierende zellinien
DE69633565T2 (de) Verpackungssysteme für humane rekombinante adenoviren, zur vewendung in der ge ntherapie
DE60024302T2 (de) Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus
DE69916005T2 (de) Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung
DE69619110T2 (de) Adenovirale vektoren für die gentherapie
DE69534166T2 (de) Rekombinanter adenovirus und methoden zu dessen verwendung
DE60035124T2 (de) Ein oncolytisches adenovirus
DE60018920T2 (de) Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
DE69934421T2 (de) Selektiv-replizierende virale vectoren
WO2018189535A1 (en) Viral vector
US20030100116A1 (en) Canine adenovirus vectors for the transfer of genes in targeted cells
EP1118670A1 (en) Canine adenovirus vectors for the transfer of genes in targeted cells
CZ296600B6 (cs) Virový vektor obsahující replikující se DNA, zpusob prípravy této DNA a farmaceutická kompozice obsahující virový vektor
WO2000073424A1 (en) A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
US20030082144A1 (en) Novel baculovirus enhancer-like sequence
DE69621949T2 (de) Toxisches protein exprimierende viren und produktionszellinien
MXPA99004449A (en) Method for producing recombinant virus
Lu Developing herpes simplex virus type 1 amplicon vectors for gene therapy: Hepatic gene transfer and steroid-inducible gene expression